To easily manufacture a fiber assembly that includes fibers and particulates supported by the fibers, provided is a method for manufacturing a fiber assembly including: a preparation step of preparing a raw material liquid that contains a water-soluble first component, a second component that is capable of forming a hydrogel, and water; and an electrospinning step of forming fibers that contain the first component as a main component and particulates that are supported by a plurality of the fibers and contain the second component from the raw material liquid by an electrospinning method, wherein in a case where the fibers contain the second component, a mass proportion of the second component contained in the particulates is greater than a mass proportion of the second component contained in the fibers.

Described herein are compositions of collagen and micronized placental tissue components, methods for producing the same and methods for using the same for wound healing, repairing damaged tendons, cosmetic applications and covering biocompatible materials and/or devices.

The present invention relates to a long-lasting medical product for protecting or treating a lesion in the gastrointestinal tract. The medical product includes a protective covering, wherein the medical product upon application at and about the site of the lesion adheres to the gastrointestinal tissue and is capable of remaining at and about the site of the lesion for a time sufficient to allow the lesion to heal or be treated.

The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (TA). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.

Compositions which self-assemble under physiological conditions are formulated for application to wounds. The formulations include a pharmaceutically acceptable carrier or are provided as part of a medical device or coating. The formulations may also include other therapeutic, prophylactic or diagnostic agents. The formulation can be administered for treatment of one or more disorders or conditions. For example, the formulation may be applied to repair an injury or during surgery of the lung, eye or dura, or following an epidural or spinal tap, to stop leakage of blood, interstitial fluid, or cerebrospinal fluid. The formulation may be administered to a burn or ulcer. In one embodiment, the formulation is provided as a dry or lyophilized powder. In another embodiment, the material is provided in water. In another embodiment, the material is provided in combination with an oil and forms a laminate.

The invention concerns a pharmaceutical composition comprising a platelet lysate and its use to treat a wound, an anal fissure, vaginal atrophy or a wrinkle.

The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and/or into the wound of a patient.

In present invention oxidation method of viscon cellulose with NO.sub.2 obtained H.sub.3PO.sub.4/HNO.sub.3 is defined liquid and gas media. Regenerated oxidise cellulose (REOC in shorten term) contain in COOH yields are standardised as 18.6-20.1 for textile, 19.8-21.5% for powder samples. Powder and textile (woven and fabric) products are impregnated 1.8-2.4% Ca.sup.+2 ion, 0-1.1% Na.sup.+1 ion, 0.8-1.5% tranexamic acid and 6-aminocaproic acid as antifibrinolytic. Obtained powder and gel products are impregnated Bi.sup.+3, Zn.sup.+2 and Ag.sup.+1 ions for antiseptic purposes. Only Bismuth of them is shown antibacterial effects. Also the aim of present invention is haemostat antimicrobial properties during impregnation of Rifampicin, Gatifloxacin, Doxycycline, Levofloxacin, Lincomycin, Clindamycin, Ciprofloxacin. Haemostatic properties are indicated for all products and antimicrobial properties are shown for some samples. Cytotoxicity, sensitivity and irritation properties are determined in compliance of Pharmacopeias.

The present invention relates to a long-lasting medical product for protecting or treating a lesion in the gastrointestinal tract. The medical product includes a protective covering, wherein the medical product upon application at and about the site of the lesion adheres to the gastrointestinal tissue and is capable of remaining at and about the site of the lesion for a time sufficient to allow the lesion to heal or be treated.

The present disclosure is directed towards an absorbent binder composition that includes a hydrophilic polymer which has the capability of post-application, moisture-induced cross-linking. The absorbent binder composition can include 1) a superabsorbent polymer material which can include at least 15 mass percent monoethylenically unsaturated polymer, such as carboxylic acid, sulphonic acid, or phosphoric acid, or salts thereof, and an acrylate or methacrylate ester that contains an alkoxysilane functionality and 2) a polyvalent metal cation having a valence of at least two. Upon loss of water by evaporation, the alkoxysilane functionality forms a silanol functional group which condenses to form a crosslinked polymer. Upon exposure of the absorbent binder composition to a biological material, such as urine, blood, or feces, the biological material can interact with the polyvalent metal cation and can serve as a catalyst to accelerate the polymer cross-linking and gelation of the polymer.